UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: June 22, 2017
(Date of earliest event reported)
LOXO ONCOLOGY, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-36562 | | 46-2996673 |
(Commission File Number) | | (IRS Employer Identification No.) |
281 Tresser Blvd., 9th Floor
Stamford, CT | | 06901 |
(Address of Principal Executive Offices) | | (Zip Code) |
(203) 653-3880
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 22, 2017, the Company held its 2017 Annual Meeting of Stockholders (“Annual Meeting”) and the following proposals were adopted:
1. Election of three Class III directors, Steven A. Elms, Alan Fuhrman and Avi Z. Naider, each to serve a three-year term, which will expire at the 2020 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified:
Nominees | | Shares For | | Shares Withheld | | Shares Abstaining | | Broker Non-Votes | |
Steven A. Elms | | 16,944,458 | | 3,810,289 | | — | | 3,868,022 | |
Alan Fuhrman | | 17,586,064 | | 3,168,683 | | — | | 3,868,022 | |
Avi Z. Naider | | 17,585,444 | | 3,169,303 | | — | | 3,868,022 | |
2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017:
Shares For | | Shares Against | | Shares Abstaining | | Broker Non-Votes | |
24,617,366 | | 4,403 | | 1,000 | | — | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Loxo Oncology, Inc. |
| | |
| | |
Date: June 23, 2017 | By: | /s/ Jennifer Burstein |
| | Name: | Jennifer Burstein |
| | Title: | Vice President of Finance and principal financial officer |
3
